“Aridis announced that the Cystic Fibrosis Foundation has expanded its research agreement to fund AR-501 (inhaled gallium-citrate for lung infections in cystic fibrosis, CF) from $2.9M to up to $7.5M. Separately, the FDA has also granted both Fast Track and QIDP Designations for AR-501, thereby enabling future Priority Review status to the program.”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.2% and a 37.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.25, representing a 210.4% upside. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
The company has a one-year high of $13.85 and a one-year low of $7.59. Currently, Aridis Pharmaceuticals Inc has an average volume of 5,956.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.